Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 509

1.

Infliximab Biosimilars in the Age of Personalized Medicine.

Kang J, Pisupati K, Benet A, Ruotolo BT, Schwendeman SP, Schwendeman A.

Trends Biotechnol. 2018 May 31. pii: S0167-7799(18)30137-9. doi: 10.1016/j.tibtech.2018.05.002. [Epub ahead of print]

PMID:
29861288
2.

Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.

Brøndum L, Alsner J, Sørensen BS, Maare C, Johansen J, Primdahl H, Evensen JF, Kristensen CA, Andersen LJ, Overgaard J, Eriksen JG.

Acta Oncol. 2018 May 17:1-6. doi: 10.1080/0284186X.2018.1464664. [Epub ahead of print]

PMID:
29771169
3.

AMYCNE: Confident copy number assessment using whole genome sequencing data.

Eisfeldt J, Nilsson D, Andersson-Assarsson JC, Lindstrand A.

PLoS One. 2018 Mar 26;13(3):e0189710. doi: 10.1371/journal.pone.0189710. eCollection 2018.

4.

Analysis of the association between Fc receptor family gene polymorphisms and ocular Behçet's disease in Han Chinese.

Zhang D, Qin J, Li L, Su G, Huang G, Cao Q, Kijlstra A, Yang P.

Sci Rep. 2018 Mar 19;8(1):4850. doi: 10.1038/s41598-018-23222-8.

5.

Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.

Arnold ML, Kainz A, Hidalgo LG, Eskandary F, Kozakowski N, Wahrmann M, Haslacher H, Oberbauer R, Heilos A, Spriewald BM, Halloran PF, Böhmig GA.

Am J Transplant. 2018 Feb 25. doi: 10.1111/ajt.14710. [Epub ahead of print]

PMID:
29478298
6.

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF.

Romero-Cara P, Torres-Moreno D, Pedregosa J, Vílchez JA, García-Simón MS, Ruiz-Merino G, Morán-Sanchez S, Conesa-Zamora P.

Int J Med Sci. 2018 Jan 1;15(1):10-15. doi: 10.7150/ijms.22812. eCollection 2018.

7.

Frequency analysis of the g.7081T>G/A and g.10872T>G polymorphisms in the FCGR3A gene (CD16A) using nested PCR and their functional specific effects.

Pérez-Romero CA, Sánchez IP, Naranjo-Piedrahita L, Orrego-Arango JC, Muskus-López CE, Rojas-Montoya W, Franco Restrepo JL, Trujillo-Vargas CM.

Genes Immun. 2018 Jan 5. doi: 10.1038/s41435-017-0001-0. [Epub ahead of print]

PMID:
29305595
8.

Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action.

Robinson JI, Baxter EW, Owen RL, Thomsen M, Tomlinson DC, Waterhouse MP, Win SJ, Nettleship JE, Tiede C, Foster RJ, Owens RJ, Fishwick CWG, Harris SA, Goldman A, McPherson MJ, Morgan AW.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E72-E81. doi: 10.1073/pnas.1707856115. Epub 2017 Dec 15.

9.

Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Victor AR, Weigel C, Scoville SD, Chan WK, Chatman K, Nemer MM, Mao C, Young KA, Zhang J, Yu J, Freud AG, Oakes CC, Caligiuri MA.

J Immunol. 2018 Jan 15;200(2):565-572. doi: 10.4049/jimmunol.1701128. Epub 2017 Dec 11.

PMID:
29229679
10.

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis.

Pál I, Szamosi S, Hodosi K, Szekanecz Z, Váróczy L.

RMD Open. 2017 Nov 1;3(2):e000485. doi: 10.1136/rmdopen-2017-000485. eCollection 2017.

11.

FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome.

Rossi GM, Bonatti F, Adorni A, Alberici F, Bodria M, Bonanni A, Ghiggeri GM, Martorana D, Vaglio A.

Immunol Lett. 2018 Jan;193:11-13. doi: 10.1016/j.imlet.2017.11.002. Epub 2017 Nov 15.

PMID:
29155175
12.

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies.

Lallemand C, Liang F, Staub F, Simansour M, Vallette B, Huang L, Ferrando-Miguel R, Tovey MG.

J Immunol Res. 2017;2017:3908289. doi: 10.1155/2017/3908289. Epub 2017 Sep 27.

13.

Genetic and Functional Profiling of CD16-Dependent Natural Killer Activation Identifies Patients at Higher Risk of Cardiac Allograft Vasculopathy.

Paul P, Picard C, Sampol E, Lyonnet L, Di Cristofaro J, Paul-Delvaux L, Lano G, Nicolino-Brunet C, Ravis E, Collart F, Dignat-George F, Dussol B, Sabatier F, Mouly-Bandini A.

Circulation. 2018 Mar 6;137(10):1049-1059. doi: 10.1161/CIRCULATIONAHA.117.030435. Epub 2017 Nov 2.

PMID:
29097449
14.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

PMID:
29042454
15.

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.

Wang W, Somers EB, Ross EN, Kline JB, O'Shannessy DJ, Schweizer C, Weil S, Grasso L, Nicolaides NC.

Cytogenet Genome Res. 2017;152(4):169-179. doi: 10.1159/000481213. Epub 2017 Oct 18.

PMID:
29041009
16.

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.

Gantke T, Weichel M, Herbrecht C, Reusch U, Ellwanger K, Fucek I, Eser M, Müller T, Griep R, Molkenthin V, Zhukovsky EA, Treder M.

Protein Eng Des Sel. 2017 Sep 1;30(9):673-684. doi: 10.1093/protein/gzx043.

PMID:
28981915
17.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD.

Ann Oncol. 2017 Nov 1;28(11):2806-2812. doi: 10.1093/annonc/mdx496.

PMID:
28945884
18.

FC gamma receptor polymorphisms in patients with immune thrombocytopenia.

Pavkovic M, Petlichkovski A, Karanfilski O, Cevreska L, Stojanovic A.

Hematology. 2018 Apr;23(3):163-168. doi: 10.1080/10245332.2017.1377902. Epub 2017 Sep 23.

PMID:
28942727
19.

Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab.

Kimura K, Kobayashi D, Hatoyama S, Yamamoto M, Takayanagi R, Yamada Y.

APMIS. 2017 Dec;125(12):1102-1107. doi: 10.1111/apm.12754. Epub 2017 Sep 15.

PMID:
28913867
20.

The genetics of Takayasu arteritis.

Renauer P, Sawalha AH.

Presse Med. 2017 Jul - Aug;46(7-8 Pt 2):e179-e187. doi: 10.1016/j.lpm.2016.11.031. Epub 2017 Jul 26.

PMID:
28756073

Supplemental Content

Loading ...
Support Center